Sungpil Han, M.D., Ph.D., is an Assistant Professor in the Department of Pharmacology at the Catholic University of Korea, College of Medicine. Combining clinical expertise with advanced pharmaceutical research, he also serves as a Director and Program Manager at AIMS BioScience, where he bridges the gap between academic innovation and drug development strategy. Dr. Han is a specialist in pharmacometrics, with extensive experience in pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation. His current research focuses on the cutting-edge application of Microphysiological Systems (MPS) to predict human pharmacokinetics. By integrating ADME (Absorption, Distribution, Metabolism, and Excretion) aspects and Drug-Drug Interaction (DDI) evaluations, his work aims to develop robust alternatives to animal testing. An active contributor to the global regulatory science community, Dr. Han is dedicated to advancing pharmacology education and fostering international collaborations to streamline the transition from preclinical research to clinical success.

Dr Zi Wang is a clinical pharmacist at Zhongshan Hospital, Fudan University, Shanghai, China. He obtained his PhD in 2020. His research focuses on antithrombotic therapy management, drug–drug interactions, and clinical pharmacokinetics in cardiovascular patients. He has conducted multiple prospective cohort studies integrating real-world data and pharmacokinetic measurements to evaluate exposure–response relationships of direct oral anticoagulants.

Professional Background 2022.09~ Present/Chungbuk National University Hospital Educational Background Ph.D. course in Pharmacology/ChungBuk National University Graduate School,Cheongju Medical Master's degree in Clinical Pharmacology&Therapeutics in Clinical Pharmacology &Therapeutics /ChungBuk National University Graduate School, Cheongju Bachelor’s degree in Biomedicinal Technology/Dong-A University,Busan Clinical Trial Background 2023 Carcinoma Phase I Hypertension Phase I Type II DM Phase I Back pain Phase I Gastrointestinal bleeding Phase I Erosive esophagitis Phase I Obesity Phase I Back pain Phase I Peptic ulcer Phase I Gastritis Phase I Pain & Upper respiratory Phase I 2024 Hypertension Phase I Type II DM Phase I Gastroesophageal reflux disease Phase I Dyslipidemia Phase I Breast cancer Phase I Essential Hypertension Bioequivalence Overactive Bladder and Benign Prostatic Hyperplasia Phase 1 2025 Obesity & Type II DM Phase 1 Chronic inflammatory demyelinating polyneuropathy(CIDP) Phase 1 Hypertension Phase 1 Inflammatory bowel disease Phase 1 Prevention and treatment of infections Phase 1 Psoriasis Phase 1

Ivana Čegec, MD, is a specialist in Clinical Pharmacology and Toxicology at the University Hospital Centre Zagreb. She graduated from the School of Medicine, University of Zagreb, in 2007 and completed her internship at UHC Zagreb. After working in outpatient clinical practice, she began her specialization in clinical pharmacology and toxicology in 2010 and passed the specialist examination with distinction in 2014. She is continuously employed at the Department of Clinical Pharmacology, where she works in inpatient care, day hospital services, outpatient clinics, and multidisciplinary consultations. Her professional focus includes rational pharmacotherapy, drug hypersensitivity diagnostics and testing, pharmacovigilance, antimicrobial stewardship, and patient safety. Dr. Čegec actively participates in clinical trials, development of national antimicrobial guidelines, and editorial work for professional journals. She is currently pursuing a PhD in Biomedicine and Health Sciences.

Dr. Andrej Belančić is a 32-year-old Specialist in Clinical Pharmacology at the Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Croatia. He also holds the academic title of Lecturer at the Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Croatia. In 2024, he received the Best Young Scientist award from the Faculty of Medicine, University of Rijeka, and in 2025 was named the best scientist in Croatia under the age of 40 by the Croatian Medical Chamber. Dr. Belančić is the author or co-author of more than 150 scientific and professional full-text articles and approximately 200 scientific abstracts. His scientific activities primarily focus on clinical pharmacology, rare diseases, obesity, and associated metabolic diseases. He is a Co-chair of the Early Career Clinical Pharmacologists Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT).

I am a Research fellow at Monash Universities centre for medicine use and safety, working on the APRICOT trial. My PhD from the University of Otago explored the impact of prescription co-payments in New Zealand through the use of discrete choice experiments to quantify the preferences of pharmacy service users and whole of population cohort studies. My skills include policy evaluation, both quantitative and qualitative analysis, and communicating findings to diverse audiences. I enjoy collaborating across sectors having worked with government, providers, and community organisations, giving me a strong grounding in real‑world policy impact.